Loading organizations...

PreciseDx is a technology company.
PreciseDx develops an AI-powered diagnostic platform, OncoIntelligence, primarily offering PreciseBreast for objective risk stratification in early-stage breast cancer. This platform utilizes artificial intelligence to analyze cellular morphology from existing tissue samples, providing a comprehensive and quantitative assessment of recurrence risk. By examining every cell on a slide, PreciseDx delivers accurate results within hours, significantly reducing the turnaround time compared to traditional gene expression testing.
The company was co-founded by Dr. Carlos Cordon-Cardo, a recognized figure in molecular pathology and the originator of systems pathology, along with Gerardo Fernandez and Michael Donovan. Dr. Cordon-Cardo's deep understanding of disease mechanisms and a personal journey as a cancer survivor inspired the creation of a system that integrates anatomical pathology with molecular biology, leveraging AI for precise diagnostic and prognostic insights. The company spun out of the Mount Sinai Health System.
PreciseDx serves oncologists, surgeons, pathologists, and patients by providing critical insights to inform treatment decisions. Its vision is to transform the future of precision medicine by translating complex data into actionable knowledge, ultimately striving to improve patient outcomes. The company is committed to advancing care through technological innovation and collaborative efforts.
PreciseDx has raised $31.7M across 2 funding rounds.
PreciseDx has raised $31.7M in total across 2 funding rounds.
PreciseDx has raised $31.7M in total across 2 funding rounds.
PreciseDx's investors include Eventide Asset Management, Merck, Philips Ventures, GenHenn Capital, Labcorp, Quest Diagnostics.
PreciseDx is an AI-driven oncology diagnostics company that commercializes a morphology-based risk‑stratification test, PreciseBreast, which analyzes standard H&E pathology slides to produce rapid, patient‑specific recurrence risk scores to support treatment decisions for early‑stage breast cancer patients[4][1]. The company leverages its OncoIntelligence platform and a patented Morphology Feature Array to quantify cellular morphology at scale and has raised institutional funding to expand commercialization after clinical validation and regulatory laboratory approvals[1][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: PreciseDx is a clinically validated, well‑funded startup translating Mount Sinai’s academic AI pathology research into a commercial, morphology‑based risk‑stratification test that aims to deliver faster, objective recurrence risk information from routine H&E slides—positioning it to accelerate adoption of digital pathology and tighter, data‑driven oncology decision making if it continues to demonstrate real‑world clinical utility and secures reimbursement[1][4][3].
PreciseDx has raised $31.7M across 2 funding rounds. Most recently, it raised $11.0M Other Equity in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 18, 2025 | $11.0M Other Equity | Eventide Asset Management, Merck, Philips Ventures | GenHenn Capital, Labcorp, Quest Diagnostics |
| Aug 21, 2024 | $20.7M Series B | Eventide Asset Management | GenHenn Capital, Labcorp, Quest Diagnostics |